Literature DB >> 25019270

The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia.

Donglei Zhang1, Huiyuan Li, Li Ma, Xian Zhang, Feng Xue, Zeping Zhou, Ying Chi, Xiaofan Liu, Yueting Huang, Yanhui Yang, Renchi Yang.   

Abstract

Chronic immune thrombocytopenia (ITP) is characterized by autoimmune-mediated platelet destruction and impairment of thrombopoiesis. Mesenchymal stem cells (MSCs) are proposed to exhibit immune modulatory functions in self-tolerance maintenance. In this study, we aimed to characterize phenotypically and functionally bone marrow (BM)-derived MSCs from adult chronic ITP patients. Our results showed that BM-MSCs from patients with chronic ITP exhibited impaired proliferation, abnormal morphology and excessive apoptosis, and these defects could be ameliorated by modifying the culture environment. BM-MSCs from chronic ITP patients were shown to have similar immunophenotype and capacities to differentiate along adipogenic and osteogenic lineages as those from normal controls. However, the immune-inhibiting potential and the regulatory T cell-inducing ability of BM-MSCs from patients were defective compared to that of normal BM-MSCs. These findings suggest that the BM-MSCs were defective in chronic ITP patients. Whether the defective BM-MSCs are relevant to the pathogenesis of chronic ITP remains to be determined.

Entities:  

Keywords:  Autoimmune; immunomodulation; mesenchymal stem cell; primary immune thrombocytopenia; regulatory T cells

Mesh:

Substances:

Year:  2014        PMID: 25019270     DOI: 10.3109/08916934.2014.938320

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  9 in total

1.  Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression.

Authors:  Jia-Min Zhang; Fei-Er Feng; Qian-Ming Wang; Xiao-Lu Zhu; Hai-Xia Fu; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Stem Cells Transl Med       Date:  2016-07-28       Impact factor: 6.940

2.  Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia.

Authors:  Jia-Min Zhang; Xiao-Lu Zhu; Jing Xue; Xiao Liu; X Long Zheng; Ying-Jun Chang; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Funct Integr Genomics       Date:  2018-02-13       Impact factor: 3.410

Review 3.  Pathogenesis and Therapeutic Mechanisms in  Immune Thrombocytopenia (ITP).

Authors:  Anne Zufferey; Rick Kapur; John W Semple
Journal:  J Clin Med       Date:  2017-02-09       Impact factor: 4.241

4.  All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-interleukin-1β loop.

Authors:  Xiaolu Zhu; Yanan Wang; Qian Jiang; Hao Jiang; Jin Lu; Yazhe Wang; Yuan Kong; Yingjun Chang; Lanping Xu; Jun Peng; Ming Hou; Xiaojun Huang; Xiaohui Zhang
Journal:  Haematologica       Date:  2019-01-24       Impact factor: 9.941

5.  miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia.

Authors:  Yanan Wang; Jiamin Zhang; Yan Su; Chencong Wang; Gaochao Zhang; Xiao Liu; Qi Chen; Meng Lv; Yingjun Chang; Jun Peng; Ming Hou; Xiaojun Huang; Xiaohui Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2020-05-01       Impact factor: 8.886

6.  Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report.

Authors:  Shiro Kimbara; Yoshinori Imamura; Kimikazu Yakushijin; Ako Higashime; Taiji Koyama; Yoshimi Fujishima; Yohei Funakoshi; Masanori Toyoda; Naomi Kiyota; Hiroshi Matsuoka; Hironobu Minami
Journal:  Mol Clin Oncol       Date:  2020-12-16

7.  Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells.

Authors:  Alessandra Di Paola; Giuseppe Palumbo; Chiara Tortora; Maura Argenziano; Marialuigia Catanoso; Caterina Di Leva; Giulia Ceglie; Silverio Perrotta; Franco Locatelli; Francesca Rossi
Journal:  Br J Haematol       Date:  2021-12-28       Impact factor: 8.615

Review 8.  Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?

Authors:  Yue Lv; Huiping Shi; Hong Liu; Lu Zhou
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

9.  Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia.

Authors:  Tian-Shu Yu; Hao-Yi Wang; Ya-Jing Zhao; Ya-Fei Yu; Yu Hou; Shuang Liu; Pan-Pan Han; Xiao-Fei Ni; Xue-Bin Ji; Jun Peng; Xin-Guang Liu; Ming Hou
Journal:  Blood Adv       Date:  2021-10-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.